-continued

aaccaatcac cttccttgat gccgaagagg gcgacatgtg tcttcacacc ctggagcgag 420

tggacccccc agtggacaac gaccgctacc cctcccactt agcctccttc gtgctggcct 480

<210> SEQ ID NO 18
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: DNA polymerase coding sequence between MLP TATA box and +1

<400> SEQUENCE: 18

Glu Asn Glu Arg Ala Pro Thr Pro
1 5

1. (canceled)

2. (canceled)

3. An adenoviral vector comprising:

(a) a plurality of adenoviral early genes;

(b) a plurality of adenoviral late genes under the control of a Major Late Promoter (MLP); and

(c) a transgene,

wherein the MLP comprises one or more repressor elements which are capable of regulating or controlling transcription of the adenoviral late genes.

4. The adenoviral vector as claimed in claim **3**, wherein the one or more repressor elements are inserted:

(i) between the MLP TATA box and the +1 position of transcription; or

(ii) downstream of the MLP TATA box.

5. The adenoviral vector as claimed in claim **3**, wherein the repressor element is one which is capable of being bound by a repressor protein.

6. The adenoviral vector as claimed in claim **3**, wherein a gene encoding a repressor protein which is capable of binding to the repressor element is encoded within the adenoviral genome.

7. The adenoviral vector as claimed in claim **5**, wherein the repressor protein is transcribed under the control of the MLP.

8. The adenoviral vector as claimed in claim **5**, wherein the repressor protein is the tetracycline repressor, the lactose repressor or the ecdysone repressor.

9. The adenoviral vector as claimed in claim **3**, wherein the repressor element is a tetracycline repressor binding site comprising or consisting of the sequence set forth in SEQ ID NO: 2.

10. The adenoviral vector as claimed in claim **3**, wherein the nucleotide sequence of the MLP comprises or consists of the sequence set forth in SEQ ID NO: 6 or 7.

11-12. (canceled)

13. (canceled)

14. (canceled)

15-16. (canceled)

17. (canceled)

18. (canceled)

19. (canceled)

20-22. (canceled)

23. (canceled)

24. (canceled)

25. (canceled)

26. (canceled)

27. (canceled)

28. (canceled)

29. (canceled)

30-31. (canceled)

32. An adenoviral vector as claimed in claim **3**, wherein the presence of the repressor element does not affect production of the adenoviral E2B protein.

33. An adenoviral vector as claimed in claim **3**, wherein the adenoviral vector encodes the adenovirus L4 100K protein and wherein the L4 100K protein is not under control of the MLP.

34. An adenoviral vector as claimed in claim **3**, wherein a transgene is inserted within one of the adenoviral early regions, or within the adenoviral E1 region.

35. An adenoviral vector as claimed in claim **3**, wherein the transgene comprises a Tripartite Leader (TPL) in its 5'-UTR.

36. An adenoviral vector as claimed in claim **3**, wherein the transgene encodes a therapeutic polypeptide.

37. An adenoviral vector as claimed in claim **3**, wherein the transgene encodes a virus protein, or a protein that is capable of assembly in or outside of a cell to produce a virus-like particle.

38. An adenoviral vector as claimed in **37**, wherein the transgene encodes Norovirus VP1 or Hepatitis B HBsAG.

39. An adenoviral vector as claimed in claim **3**, wherein the transgene encodes an AAV Rep polypeptide, an MV Cap polypeptide, an MV Rep-Cap polypeptide and/or the transgene encodes a MV genome.

40. A composition comprising an adenovirus particle comprising an adenoviral vector as claimed in claim **3**, together with one or more physiologically-acceptable carriers, excipients or diluents.

41. A kit comprising an adenoviral vector as claimed in claim **3**, wherein the kit additionally comprises one or more additional components selected from the group consisting of: